nCounter® Breast Cancer 360™ Panel
Helping Your Research
Want a system that provides a unique 360° view of gene expression for the breast tumor, microenvironment, and immune response? If yes, then you have found the right product. The Human nCounter Breast Cancer 360 panel and data analysis report helps researchers quickly decode the complexities of breast cancer biology, develop novel breast cancer gene signatures, and categorize disease heterogeneity using 48 biological signatures including signatures based upon the validated PAM50 and Tumor Inflammation Signature (TIS) assays. Get the most out of your panel by quickly distilling a large amount of data into actionable signatures measuring variables crucial to breast tumor-immune interaction.
Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.
How It Works
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel pro
Find Your Panel
Product Information
Includes expertly curated 776 genes across 23 categories of breast cancer tumor biology to support the evaluation of pathways and process, as well as novel signature development.
Content included in the Breast Cancer 360 panel allows for a more comprehensive measurement of biological variables crucial to tumor progression and response to a wide-range of treatments. Research signatures are enriched with potentially predictive genes involved in proliferation, endothelial, angiogenesis, cytotoxicity, stroma, inflammatory chemokines, and apoptosis.
- 48 signatures including two analytically validated signatures- PAM501,2 and Tumor Inflammation Signature3
- 10 research-focused signatures and 30 novel signatures measuring important tumor and immune activities
- adapted to decode breast cancer biology in concert
Analytically Validated Signatures
PAM50 Signature1,2
Included with the Breast Cancer 360 panel is the PAM50 Signature. This 50-gene signature measures a gene expression profile that allows for the classification of breast cancer into four biologically distinct subtypes and a prognostic score.
- PAM50 Subtype
- Luminal A
- Luminal B
- HER2-Enriched
- Basal-like
- Prosigna Score / Risk of Recurrence
Tumor Inflammation Signature3
Included with the Breast Cancer 360 panel is the Tumor Inflammation Signature. This 18-gene signature measures activity known to be associated with response to PD-1/PD-L1 inhibitors pathway blockade3.
- Includes 4 areas of immune biology used to determine peripherally suppressed immune response and the identification of “hot” or “cold” tumors
- Antigen Presenting Cells
- T Cell/NK presence
- IFNγ Biology
- T Cell Exhaustion
- Tissue-of-origin agnostic (Pan-cancer)
- Potential surrogate for PD-L1 and mutational load in research setting4
View publication and video.
360 Series Product Comparison
Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.
Publications
Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer.
Neuronal nerve processes in the tumor microenvironment were highlighted recently. However, the origin of intra-tumoral nerves remains poorly known, in part because of technical difficulties in tracing nerve fibers via conventional histological preparations.
Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer.
Purpose: Cancer-associated fibroblasts (CAF) have been implicated as potential mediators of checkpoint immunotherapy response. However, the extensive heterogeneity of these cells has precluded rigorous understanding of their immunoregulatory role in the tumor microenvironment.
Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy.
Background: Genetically engineered T-cell immunotherapies for adoptive cell transfer (ACT) have emerged as a promising form of cancer treatment, but many of these patients develop recurrent disease. Furthermore, delineating mechanisms of resistance may be challenging since the analysis of bulk tumor profiling can be complicated by spatial heterogeneity.
Contact Us
Have questions or simply want to learn more?
Contact our helpful experts and we’ll be in touch soon.